Los Angeles Capital Management LLC Purchases 18,558 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Los Angeles Capital Management LLC lifted its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 9.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 219,997 shares of the company’s stock after buying an additional 18,558 shares during the quarter. Los Angeles Capital Management LLC owned about 0.63% of RAPT Therapeutics worth $348,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Medicxi Ventures Management Jersey Ltd acquired a new stake in RAPT Therapeutics during the 4th quarter worth about $35,316,000. SG Americas Securities LLC boosted its position in shares of RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after purchasing an additional 42,636 shares in the last quarter. JPMorgan Chase & Co. grew its stake in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after purchasing an additional 25,130 shares during the period. Barclays PLC increased its holdings in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new position in RAPT Therapeutics in the third quarter valued at approximately $36,000. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $1.05 on Tuesday. RAPT Therapeutics, Inc. has a one year low of $0.79 and a one year high of $10.05. The company has a market cap of $36.71 million, a PE ratio of -0.38 and a beta of 0.03. The firm has a 50-day moving average of $1.30 and a 200-day moving average of $1.58.

Analyst Ratings Changes

Several brokerages have recently commented on RAPT. Wells Fargo & Company reduced their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $2.00 in a report on Monday, November 11th. HC Wainwright upgraded shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Thursday, December 26th. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.